- ICH GCP
- Registr klinických studií v USA
- Klinická studie NCT07946666
A Clinical Trial to Evaluate the Effects of the Synbiotic Dual Cap® on Gastrointestinal Comfort in Adults Initiating GLP-1 or Dual-Incretin Therapy for Weight Loss.
This is a decentralized, single-group, open-label clinical trial evaluating the effects of the Synbiotic Dual Cap® in 40 adults who have initiated GLP-1 or dual-incretin therapy within the preceding 60 days and who are experiencing at least one associated gastrointestinal symptom. All participants will receive the Synbiotic Dual Cap® (1 capsule daily, taken in the morning without food) alongside their existing GLP-1 medication for 12 consecutive weeks.
Participants will complete study-specific questionnaires at four assessment timepoints: Baseline, Week 4, Week 8, and Week 12. No placebo control arm is included; all efficacy comparisons are within-subject against Baseline values. The study is conducted entirely remotely via the Citruslabs digital platform, with the study product shipped directly to participants' homes.
Přehled studie
Postavení
Podmínky
Intervence / Léčba
Typ studie
Zápis (Odhadovaný)
Fáze
- Nelze použít
Kontakty a umístění
Studijní kontakt
- Jméno: Dimitra Diamantopoulou
- E-mail: dimitra@epetome.com
Studijní místa
-
-
Nevada
-
Las Vegas, Nevada, Spojené státy, 89101
- Citruslabs
-
-
Kritéria účasti
Kritéria způsobilosti
Věk způsobilý ke studiu
Přijímá zdravé dobrovolníky
Pohlaví způsobilá ke studiu
Popis
Inclusion Criteria:
- Adults aged 18-65 years.
- Have initiated a GLP-1 receptor agonist or dual-incretin medication for weight loss (including but not limited to semaglutide, tirzepatide, or liraglutide) within the last 60 days prior to the date of enrollment.
- Self-reported experience of at least one gastrointestinal symptom associated with GLP-1 initiation, including nausea, bloating, constipation, diarrhea, or general digestive discomfort, at the time of screening.
- Currently on a stable GLP-1 dose as directed by their prescribing physician.
- Willing to take one Synbiotic Dual Cap® daily for 12 consecutive weeks alongside their existing GLP-1 medication and complete all questionnaire assessments at Baseline, Week 4, Week 8, and Week 12.
- Willing and able to provide informed consent prior to enrollment.
- In good general health (GLP-1 use and associated weight-related conditions do not disqualify a participant).
- Reside in the United States.
Exclusion Criteria:
- Currently pregnant or breastfeeding (or planning to become pregnant during the study period).
- Currently taking other fibre, probiotic, prebiotic, or synbiotic supplements that cannot be discontinued for the study period.
- Diagnosed with a chronic gastrointestinal condition requiring active prescription medical management - including Crohn's disease, ulcerative colitis, coeliac disease, GERD, or gastroparesis - that would independently confound GI symptom endpoints.
- Use of antibiotics or prescription gastrointestinal medications within the past 30 days prior to enrollment, or intentions to use these medications during the study period.
- Anyone currently participating or planning to participate in another research study during the study period.
- Currently receiving immunosuppressant therapy of any kind.
- Currently undergoing cancer treatment or have had a serious illness requiring hospitalization in the last three months.
- Reside in Hawaii.
- Known allergy or hypersensitivity to any ingredient in the Synbiotic Dual Cap®.
Studijní plán
Jak je studie koncipována?
Detaily designu
- Primární účel: Léčba
- Přidělení: N/A
- Intervenční model: Přiřazení jedné skupiny
- Maskování: Žádné (otevřený štítek)
Zbraně a zásahy
Skupina účastníků / Arm |
Intervence / Léčba |
|---|---|
|
Experimentální: Synbiotic Dual Cap® Arm
|
Participants will take 1 capsule each morning, without food and without a hot drink, for 12 consecutive weeks alongside their existing GLP-1 medication. |
Co je měření studie?
Primární výstupní opatření
Měření výsledku |
Popis opatření |
Časové okno |
|---|---|---|
|
Change in Overall Gastrointestinal Comfort
Časové okno: Baseline to Week 12
|
Within-subject change from Baseline in overall gastrointestinal comfort severity, assessed using study-specific questionnaires |
Baseline to Week 12
|
|
Change in Bowel Regularity
Časové okno: Baseline to Week 12
|
Within-subject change from Baseline in bowel regularity, assessed using study-specific questionnaires |
Baseline to Week 12
|
|
Change in Bloating
Časové okno: Baseline to Week 12
|
Within-subject change from Baseline in bloating severity and frequency, assessed using study-specific questionnaires |
Baseline to Week 12
|
|
Change in Constipation
Časové okno: Baseline to Week 12
|
Within-subject change from Baseline in constipation severity and frequency, assessed using study-specific questionnaires |
Baseline to Week 12
|
|
Change in Diarrhea
Časové okno: Baseline to Week 12
|
Within-subject change from Baseline in diarrhea severity and frequency, assessed using study-specific questionnaires |
Baseline to Week 12
|
|
Change in Nausea
Časové okno: Baseline to Week 12
|
Within-subject change from Baseline in nausea severity and frequency, assessed using study-specific questionnaires |
Baseline to Week 12
|
|
Change in Post-Meal Fullness Comfort
Časové okno: Baseline to Week 12
|
Within-subject change from Baseline in comfort with post-meal fullness, assessed using study-specific questionnaires |
Baseline to Week 12
|
Sekundární výstupní opatření
Měření výsledku |
Popis opatření |
Časové okno |
|---|---|---|
|
Participant Perception of Effect on Overall Gastrointestinal Comfort
Časové okno: Week 4, Week 8, and Week 12
|
Participants' self-reported perception of the product's tolerability and effect on overall gastrointestinal comfort, assessed using questionnaires |
Week 4, Week 8, and Week 12
|
|
Participant Perception of Effect on Bowel Regularity
Časové okno: Week 4, Week 8, and Week 12
|
Participants' self-reported perception of the product's tolerability and effect on bowel regularity, assessed using questionnaires |
Week 4, Week 8, and Week 12
|
|
Participant Perception of Effect on Bloating
Časové okno: Week 4, Week 8, and Week 12
|
Participants' self-reported perception of the product's tolerability and effect on bloating, assessed using questionnaires |
Week 4, Week 8, and Week 12
|
|
Participant Perception of Effect on Constipation
Časové okno: Week 4, Week 8, and Week 12
|
Participants' self-reported perception of the product's tolerability and effect on constipation, assessed using questionnaires |
Week 4, Week 8, and Week 12
|
|
Participant Perception of Effect on Diarrhea
Časové okno: Week 4, Week 8, and Week 12
|
Participants' self-reported perception of the product's tolerability and effect on diarrhea, assessed using questionnaires |
Week 4, Week 8, and Week 12
|
|
Participant Perception of Effect on Nausea
Časové okno: Week 4, Week 8, and Week 12
|
Participants' self-reported perception of the product's tolerability and effect on nausea, assessed using questionnaires |
Week 4, Week 8, and Week 12
|
|
Participant Perception of Effect on Post-Meal Fullness Comfort
Časové okno: Week 4, Week 8, and Week 12
|
Participants' self-reported perception of the product's tolerability and effect on post-meal fullness comfort, assessed using questionnaires |
Week 4, Week 8, and Week 12
|
Spolupracovníci a vyšetřovatelé
Sponzor
Spolupracovníci
Termíny studijních záznamů
Hlavní termíny studia
Začátek studia (Odhadovaný)
Primární dokončení (Odhadovaný)
Dokončení studie (Odhadovaný)
Termíny zápisu do studia
První předloženo
První předloženo, které splnilo kritéria kontroly kvality
První zveřejněno (Aktuální)
Aktualizace studijních záznamů
Poslední zveřejněná aktualizace (Aktuální)
Odeslaná poslední aktualizace, která splnila kritéria kontroly kvality
Naposledy ověřeno
Více informací
Termíny související s touto studií
Další relevantní podmínky MeSH
- Onemocnění endokrinního systému
- Poruchy výživy
- Metabolické choroby
- Nadměrná výživa
- Tělesná hmotnost
- Příznaky a symptomy, zažívací
- Poruchy metabolismu glukózy
- Diabetes Mellitus
- Nadváha
- Patologické stavy, příznaky a symptomy
- Nutriční a metabolické nemoci
- Příznaky a symptomy
- Obezita
- Diabetes mellitus, typ 2
- Nevolnost
- Zácpa
- Průjem
Další identifikační čísla studie
- EPETO-21217
Informace o lécích a zařízeních, studijní dokumenty
Studuje lékový produkt regulovaný americkým FDA
Studuje produkt zařízení regulovaný americkým úřadem FDA
Tyto informace byly beze změn načteny přímo z webu clinicaltrials.gov. Máte-li jakékoli požadavky na změnu, odstranění nebo aktualizaci podrobností studie, kontaktujte prosím register@clinicaltrials.gov. Jakmile bude změna implementována na clinicaltrials.gov, bude automaticky aktualizována i na našem webu .